Sugi Predict

Sugi Predict / Compounds / SCHEMBL145997

SCHEMBL145997

SCHEMBL145997

COc1ccc([N+](=O)[O-])cc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.64
▸ HTT P42858 2/20 0.61
▸ LMNA P02545 3/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ CYP19A1 P11511 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ PKM P14618 1/20 0.50
▸ TTR P02766 1/20 0.50
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ AMY1A P0DUB6 2/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ POLB P06746 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31144295 1.00 TDP1 (0.64) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL4435513 0.91 TDP1 (0.54) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL31463557 0.88 TDP1 (0.50) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL282839 0.85 HTT (0.66) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL29683621 0.85 HSPB1 (0.49) TDP1HTTLMNATTRMEN1
SCHEMBL21905001 0.84 MEN1 (0.51) TDP1HTTLMNAPKMMEN1
SCHEMBL13578659 0.82 TDP1 (0.49) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL3793589 0.82 HTR2A (0.54) TDP1HTTSMN1; SMN2CYP19A1PTGS2
SCHEMBL527567 0.82 HTT (0.72) TDP1HTTLMNASMN1; SMN2CYP19A1
SCHEMBL29441283 0.82 HTT (0.72) TDP1HTTLMNASMN1; SMN2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116903481-A Preparation method of alpha-hydroxy-gamma-aminobutyric acid compound 华南理工大学 2023-10-20 — — CN claimed
CN-106986880-B A kind of preparation method of the FSH antagonists with benzopyran structure 上海博栋化学科技有限公司 2018-10-23 — — CN claimed
CN-106986880-A A kind of preparation method of the FSH antagonists with benzopyran structure 毛阿龙 2017-07-28 — — CN claimed
CN-102199099-A Method for preparing 3-bromo-4-methoxyaniline UNIV CHANGZHOU 2011-09-28 — — CN claimed
EP-1963337-B1 THIENO[2,3-b]PYRIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2010-09-01 — — EP claimed
US-20100022521-A1 COMPOUNDS HANSA METALLWERKE AG (DE) 2010-01-28 — — US claimed
EP-1963337-A1 NEW COMPOUNDS Richter Gedeon NYRT (HU) 2008-09-03 — — EP claimed
WO-2007072095-A1 NEW COMPOUNDS RICHTER GEDEON NYRT. (HU) 2007-06-28 — — WO claimed
EP-4720037-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF 16380026 Canada Inc. (CA) 2026-04-08 — — EP disclosed
EP-4720036-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF 16380026 Canada Inc. (CA) 2026-04-08 — — EP disclosed
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 — — US disclosed
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2026-01-29 — — US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 — — US disclosed
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2025-06-12 — — US disclosed
WO-1997030055-A1 SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1997-08-21 — — WO disclosed
WO-1997019084-A1 SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 1997-05-29 — — WO disclosed
US-5441969-A Imidazole compounds, their preparation and use NEUROSEARCH A/S (DK) 1995-08-15 — — US disclosed
EP-0637300-A1 ANTIPROLIFERATIVE QUINAZOLINES AGOURON PHARMACEUTICALS, INC. (US) 1995-02-08 — — EP disclosed
EP-0604353-A1 Benzimidazole compounds, their preparation and use NEUROSEARCH A/S (DK) 1994-06-29 — — EP disclosed
WO-1993020055-A1 ANTIPROLIFERATIVE QUINAZOLINES AGOURON PHARMACEUTICALS, INC. (US) 1993-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022521-A1 COMPOUNDS GRM5, GRM3, GRM1 TDP1 4084/4885HTT 1879/4885LMNA 4585/4885
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds CYP1B1, CYP1A1, PAH TDP1 558/4885HTT 785/4885LMNA 1860/4885
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds KAT2B, KAT2A, KAT6A TDP1 1026/4885HTT 305/4885LMNA 2834/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 TDP1 4000/4885HTT 4847/4885LMNA 2111/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 TDP1 3712/4885HTT 4810/4885LMNA 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.